



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	GHOST (3) CCR1+ Cells
Catalog Number:	3680
Lot Number:	030506
Release Category:	C
Provided:	1 vial frozen cells.
Cell Type:	HOS (human osteosarcoma) cells
Propagation Medium:	High glucose DMEM, 90%; fetal bovine serum, 10%. Supplement with 500 µg/ml G418, 100 µg/ml hygromycin, pen/strep, and 1 µg/ml puromycin [NOTE: GHOST (3) Parental Cell Line is puromycin sensitive, do not supplement with puromycin.]
Freeze Medium:	FBS, 90%; DMSO, 10%.
Sterility:	Negative for mycoplasma, bacteria, and fungi.
Description:	The GHOST (3) CCR1+ cells express CD4 and CCR1. The tat-dependent HIV-2 LTR-GFP construct produces GFP in response to infection.
Special Characteristics:	<p>GHOST (3) parental cells are derived from HOS (human osteosarcoma) cells that were stably transduced with a MV7neo-T4 retroviral vector as well as stably cotransfected with a HIV-2 LTR-GFP construct and the CMV IE driving hygro-resistance construct. The GHOST (3) parental cell line was then transduced with retroviral vectors containing various HIV coreceptors. For a full listing, please see Table 1 below.</p> <p><u>GHOST (3) Parent Cell Line:</u> Progenitor cell line used to develop GHOST (3) indicator panel. They are adherent cells.</p> <p><u>GHOST Cell Transformants:</u> Indicator cells for HIV-1, HIV-2, or SIV infection with uncloned, primary isolates, molecular clones, or pseudotyped virus. The puromycin-resistant cells are pools rather than clones for human coreceptor expression. Adherent cells.</p>

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage:	Liquid nitrogen
Contributor:	Dr. Vineet N. KewalRamani and Dr. Dan R. Littman.
References:	Morner A, Bjorndal A, KewalRamani V, Littman DR, Inoue R, Thorstensson R, Fenyo EM, Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. <i>J Virol</i> 73 :2343-2349, 1999.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: (specify reagent) from Dr. Vineet N. KewalRamani and Dr. Dan R. Littman." Also include the reference cited above in any publications. Patent pending. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the New York University Office of Industrial Liaison at the following email address: abram.goldfinger@nyumc.org
Last Updated	June 22, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.